NO20062765L - Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse - Google Patents
Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disseInfo
- Publication number
- NO20062765L NO20062765L NO20062765A NO20062765A NO20062765L NO 20062765 L NO20062765 L NO 20062765L NO 20062765 A NO20062765 A NO 20062765A NO 20062765 A NO20062765 A NO 20062765A NO 20062765 L NO20062765 L NO 20062765L
- Authority
- NO
- Norway
- Prior art keywords
- carrier
- amino acid
- processes
- preparation
- acid residues
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53048103P | 2003-12-17 | 2003-12-17 | |
PCT/US2004/044093 WO2005058941A2 (en) | 2003-12-17 | 2004-12-17 | Aβ IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062765L true NO20062765L (no) | 2006-09-14 |
Family
ID=34700143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062765A NO20062765L (no) | 2003-12-17 | 2006-06-13 | Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse |
Country Status (26)
Country | Link |
---|---|
US (5) | US8227403B2 (sl) |
EP (4) | EP1699810A4 (sl) |
JP (1) | JP4696079B2 (sl) |
KR (2) | KR101201120B1 (sl) |
CN (1) | CN1934127B (sl) |
AR (1) | AR047062A1 (sl) |
AU (2) | AU2004299512B2 (sl) |
BR (1) | BRPI0417689A8 (sl) |
CA (1) | CA2549552A1 (sl) |
CR (1) | CR8445A (sl) |
DK (1) | DK2336147T3 (sl) |
EA (2) | EA009559B1 (sl) |
EC (1) | ECSP066646A (sl) |
ES (1) | ES2474173T3 (sl) |
HK (2) | HK1104826A1 (sl) |
IL (2) | IL176250A (sl) |
MX (1) | MXPA06006821A (sl) |
MY (1) | MY144231A (sl) |
NO (1) | NO20062765L (sl) |
PL (1) | PL2336147T3 (sl) |
PT (1) | PT2336147E (sl) |
SG (2) | SG149039A1 (sl) |
SI (1) | SI2336147T1 (sl) |
TW (2) | TWI379839B (sl) |
UA (1) | UA84728C2 (sl) |
WO (1) | WO2005058941A2 (sl) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1594969B1 (en) * | 2003-02-01 | 2015-05-20 | Janssen Sciences Ireland UC | Active immunization to generate antibodies to soluble a-beta |
TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
PT1701968E (pt) * | 2003-12-17 | 2015-09-11 | Wyeth Llc | Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos |
DK2336147T3 (da) | 2003-12-17 | 2014-06-10 | Wyeth Llc | Beta-immunogen-peptid-bærerkonjugater og fremgangsmåder til fremstilling deraf |
EP1711208A2 (en) * | 2004-01-28 | 2006-10-18 | Curix APS | Conjugates of amyloid proteins as vaccines for amyloid-related diseases |
CA2582157A1 (en) * | 2004-10-05 | 2006-04-20 | Wyeth | Methods and compositions for improving recombinant protein production |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
EP1896504B1 (en) | 2005-06-17 | 2012-11-21 | Wyeth LLC | Methods of purifying fc region containing antibodies |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EP2468770B1 (en) | 2006-07-14 | 2017-12-20 | AC Immune S.A. | Humanized antibody against amyloid beta. |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
WO2008124646A2 (en) * | 2007-04-06 | 2008-10-16 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Use of amyloid proteins as vaccine scaffolds |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US8106015B2 (en) * | 2007-04-20 | 2012-01-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
WO2009029686A1 (en) | 2007-08-27 | 2009-03-05 | Longhorn Vaccines & Diagnostics Llc | Immunogenic compositions and methods |
EP2535428B1 (en) | 2007-10-01 | 2015-09-09 | Longhorn Vaccines and Diagnostics, LLC | Biological specimen collection and transport system and methods of use |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
EP2586795B1 (en) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
ITNA20080006A1 (it) * | 2008-01-28 | 2009-07-29 | Consiglio Nazionale Ricerche | Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp |
WO2010016912A2 (en) * | 2008-08-07 | 2010-02-11 | Mercia Pharma, Llc | Immunotherapeutic compositions for the treatment of alzheimer's disease |
KR101640147B1 (ko) * | 2008-10-16 | 2016-07-18 | 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 변성된 아밀로이드 베타 펩티드 |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
DE102008037564A1 (de) * | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
EP2258398A1 (en) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
AR080446A1 (es) | 2010-03-03 | 2012-04-11 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta (beta amiloide) |
WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
CN102279269A (zh) * | 2011-04-12 | 2011-12-14 | 王贤俊 | 胱抑素c检测剂盒的制备方法 |
JP6048845B2 (ja) * | 2011-06-01 | 2016-12-21 | シャモン ユニヴァーシティー | ジフテリア毒素の無毒性突然変異体crm197又はその断片を含む融合タンパク質 |
WO2013013056A1 (en) * | 2011-07-19 | 2013-01-24 | New York University | Method for treating amyloid disease |
GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
US9504759B2 (en) | 2011-08-11 | 2016-11-29 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
KR102129220B1 (ko) * | 2011-09-23 | 2020-07-02 | 에이씨 이뮨 에스.에이. | 백신 요법 |
WO2013112916A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
DK2668959T3 (en) * | 2012-05-31 | 2015-01-26 | Innavirvax | Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein |
KR101451797B1 (ko) * | 2012-11-07 | 2014-10-16 | 가천대학교 산학협력단 | 멀티머-형성 폴리펩타이드의 멀티머 정량분석을 위한 표준 단백질 복합체 |
US10272144B2 (en) * | 2013-07-31 | 2019-04-30 | Bioventures, Llc | Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens |
EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CN104069504B (zh) * | 2014-05-11 | 2019-09-24 | 江苏康泰生物医学技术有限公司 | 一种增强多糖蛋白结合物免疫原性的方法 |
CA2959477C (en) * | 2014-06-11 | 2020-10-20 | Riken | Multiplexed same type-antigenic peptide |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
CA2985652C (en) | 2015-05-14 | 2020-03-10 | Gerald W. FISHER | Rapid methods for the extraction of nucleic acids from biological samples |
AU2017300965B2 (en) * | 2016-07-21 | 2024-09-12 | Vac4All Pte. Ltd. | Biofusion proteins as anti-malaria vaccines |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CA3095216A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
WO2020257315A1 (en) * | 2019-06-18 | 2020-12-24 | Citranvi Biosciences, Llc | Multiple antigen protein displayed adjuvant systems |
CA3197971A1 (en) | 2020-11-13 | 2022-05-19 | Andrew Lawrence Feldhaus | Protein-based nanoparticle vaccine for metapneumovirus |
US11571481B2 (en) | 2020-12-21 | 2023-02-07 | Cornell University | Peptide-linked drug delivery system |
CN114137203A (zh) * | 2021-10-21 | 2022-03-04 | 广州万孚生物技术股份有限公司 | 抗原与碱性磷酸酶结合物的制备方法 |
WO2023225562A1 (en) | 2022-05-17 | 2023-11-23 | Icosavax, Inc. | Multivalent vaccine for paramyxoviruses and uses thereof |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2982084A (en) * | 1957-05-29 | 1961-05-02 | Ebauches Sa | Alarm device |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5126131A (en) * | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
US4882317A (en) * | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5089603A (en) * | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
US5192540A (en) | 1988-04-19 | 1993-03-09 | American Cyanamid Company | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
ES2109945T3 (es) | 1990-06-01 | 1998-02-01 | Chiron Corp | Composiciones y procedimientos para identificar moleculas biologicamente activas. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
JP2001524926A (ja) | 1991-09-18 | 2001-12-04 | アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ | オリゴマーの雑多ライブラリーの集合体を合成する方法 |
JPH07507854A (ja) | 1991-12-23 | 1995-08-31 | ツォッヒェ,ミヒャエル | 油除去装置を備えたエンジン |
CA2129899C (en) * | 1992-02-11 | 2011-01-04 | James J. Mond | Dual carrier immunogenic construct |
EP0665897B1 (en) | 1992-10-01 | 2003-07-09 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
PT616034E (pt) | 1993-03-05 | 2005-02-28 | Wyeth Corp | Plasmideo para a producao de proteina crm e toxina da difteria |
ES2318848T3 (es) | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. |
CA2175587A1 (en) | 1993-11-02 | 1995-05-11 | Jeffrey H. Sugarman | Synthesizing and screening molecular diversity |
US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
IL115933A0 (en) | 1995-11-09 | 1996-01-31 | Oramir Semiconductor Ltd | Process and apparatus for oblique beam revolution for the effective laser stripping of sidewalls |
NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
CA2751712C (en) | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
US6962984B2 (en) | 1996-12-05 | 2005-11-08 | Nihon University | IgA nephropathy-related DNA |
DE69612205T2 (de) | 1996-12-16 | 2001-08-30 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Verfahren zur Kupplung von Polysacchariden und Proteinen |
US5877220A (en) * | 1997-03-06 | 1999-03-02 | Genta, Incorporated | Amide-based oligomeric cationic lipids |
US20020086847A1 (en) * | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US7588766B1 (en) * | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
GB2333706A (en) | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
MXPA00008352A (es) | 1998-02-27 | 2002-10-17 | Univ Pennsylvania | Vacunas, composiciones inmunoterapeuticas y metodos para usar las mismas. |
CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
US6645503B1 (en) * | 1998-03-10 | 2003-11-11 | Wyeth Holdings Corporation | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria |
US20050059591A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20050059802A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
DK1117435T3 (da) | 1998-09-30 | 2008-03-17 | Wyeth Corp | Muteret cholera-holotoxin som adjuvans |
US6245015B1 (en) * | 1998-12-07 | 2001-06-12 | General Electric Company | Photosonic diffusion wave-based tumor detector |
CA2363118A1 (en) * | 1999-02-25 | 2000-08-31 | Smithkline Beecham Biologicals S.A. | Immunogens comprising a peptide and a carrier derived from h.influenzae protein d |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
US6945135B1 (en) * | 1999-09-09 | 2005-09-20 | L. H. Thomson Company, Inc. | Bicycle stem for enlarged handlebar portions and associated methods |
GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
CN1433321A (zh) * | 1999-11-29 | 2003-07-30 | 尼奥切姆公司 | 预防和治疗Alzheimer症和其他与淀粉样蛋白有关的疾病的疫苗 |
HUP0300067A3 (en) | 2000-02-21 | 2010-03-29 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
US20030190322A1 (en) * | 2000-03-31 | 2003-10-09 | Peter Kaastrup | Immunostimulating properties of a fragment of tgf-beta |
EP1284998B1 (en) * | 2000-05-22 | 2004-12-29 | New York University | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
JP2004509846A (ja) | 2000-06-02 | 2004-04-02 | メルク エンド カムパニー インコーポレーテッド | 肝炎c型ウイルスコンジュゲート |
US20030092145A1 (en) | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
US7033593B2 (en) | 2000-09-22 | 2006-04-25 | Duke University | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |
KR100863368B1 (ko) | 2000-11-10 | 2008-10-13 | 와이어쓰 홀딩스 코포레이션 | 조합 보조 제제 |
US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
US20030224011A1 (en) * | 2001-05-29 | 2003-12-04 | Conley Anthony J | Hepatitis c virus conjugates |
JP2005508143A (ja) | 2001-06-07 | 2005-03-31 | ワイス・ホールデイングス・コーポレーシヨン | アジュバントとしてのコレラホロトキシンの突然変異形 |
IL159210A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
US20030135035A1 (en) * | 2001-08-09 | 2003-07-17 | Mark Shannon | Human ZZAP1 protein |
EP1572894B1 (en) * | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
ES2361907T3 (es) * | 2001-12-20 | 2011-06-24 | Randox Laboratories Ltd. | Haptenos, inmunógenos, anticuerpos y conjugados para lsd 2-oxo-3-hidroxi. |
FR2833840B1 (fr) * | 2001-12-21 | 2010-06-18 | Rytek | Methodes et compositions pour le traitement de pathologies respiratoires |
AU2003231279A1 (en) | 2002-04-30 | 2003-11-17 | Wyeth Holdings Corporation | Prevention and treatment of type 2 diabetes |
CN1656725A (zh) * | 2002-05-28 | 2005-08-17 | 皇家飞利浦电子股份有限公司 | 由接收器对出错帧进行校正的方法 |
KR20050101537A (ko) * | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
CN102366630B (zh) | 2003-03-07 | 2015-04-01 | 惠氏控股公司 | 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物 |
CA2519511A1 (en) * | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
CN100409896C (zh) | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
PT1701968E (pt) * | 2003-12-17 | 2015-09-11 | Wyeth Llc | Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos |
DK2336147T3 (da) * | 2003-12-17 | 2014-06-10 | Wyeth Llc | Beta-immunogen-peptid-bærerkonjugater og fremgangsmåder til fremstilling deraf |
JP5045349B2 (ja) | 2007-10-01 | 2012-10-10 | パナソニック株式会社 | 左手系フィルタ |
-
2004
- 2004-12-17 DK DK11151428.7T patent/DK2336147T3/da active
- 2004-12-17 EP EP04817081A patent/EP1699810A4/en not_active Withdrawn
- 2004-12-17 EA EA200601168A patent/EA009559B1/ru not_active IP Right Cessation
- 2004-12-17 KR KR1020117020349A patent/KR101201120B1/ko not_active IP Right Cessation
- 2004-12-17 SI SI200432170T patent/SI2336147T1/sl unknown
- 2004-12-17 EA EA200702209A patent/EA011239B1/ru not_active IP Right Cessation
- 2004-12-17 KR KR1020067014293A patent/KR101158147B1/ko not_active IP Right Cessation
- 2004-12-17 CN CN200480041798.9A patent/CN1934127B/zh not_active Expired - Fee Related
- 2004-12-17 WO PCT/US2004/044093 patent/WO2005058941A2/en active Application Filing
- 2004-12-17 AU AU2004299512A patent/AU2004299512B2/en not_active Ceased
- 2004-12-17 TW TW100140530A patent/TWI379839B/zh not_active IP Right Cessation
- 2004-12-17 EP EP12157147.5A patent/EP2479184A3/en not_active Withdrawn
- 2004-12-17 TW TW093139610A patent/TWI357414B/zh not_active IP Right Cessation
- 2004-12-17 EP EP11151428.7A patent/EP2336147B1/en active Active
- 2004-12-17 ES ES11151428.7T patent/ES2474173T3/es active Active
- 2004-12-17 SG SG200809362-7A patent/SG149039A1/en unknown
- 2004-12-17 PT PT111514287T patent/PT2336147E/pt unknown
- 2004-12-17 SG SG2012043139A patent/SG182189A1/en unknown
- 2004-12-17 CA CA002549552A patent/CA2549552A1/en not_active Abandoned
- 2004-12-17 PL PL11151428T patent/PL2336147T3/pl unknown
- 2004-12-17 US US10/583,503 patent/US8227403B2/en not_active Expired - Fee Related
- 2004-12-17 MX MXPA06006821A patent/MXPA06006821A/es active IP Right Grant
- 2004-12-17 EP EP12157140A patent/EP2460813A1/en not_active Withdrawn
- 2004-12-17 UA UAA200608020A patent/UA84728C2/ru unknown
- 2004-12-17 AR ARP040104758A patent/AR047062A1/es not_active Application Discontinuation
- 2004-12-17 BR BRPI0417689A patent/BRPI0417689A8/pt not_active IP Right Cessation
- 2004-12-17 JP JP2006545618A patent/JP4696079B2/ja not_active Expired - Fee Related
- 2004-12-17 MY MYPI20045205A patent/MY144231A/en unknown
-
2006
- 2006-06-08 CR CR8445A patent/CR8445A/es unknown
- 2006-06-12 IL IL176250A patent/IL176250A/en not_active IP Right Cessation
- 2006-06-13 NO NO20062765A patent/NO20062765L/no not_active Application Discontinuation
- 2006-06-15 EC EC2006006646A patent/ECSP066646A/es unknown
-
2007
- 2007-08-20 US US11/841,919 patent/US9095536B2/en not_active Expired - Fee Related
- 2007-08-20 US US11/841,993 patent/US20080299074A1/en not_active Abandoned
- 2007-09-21 HK HK07110272.1A patent/HK1104826A1/xx not_active IP Right Cessation
-
2011
- 2011-02-24 AU AU2011200785A patent/AU2011200785B2/en not_active Ceased
- 2011-05-26 IL IL213156A patent/IL213156A/en not_active IP Right Cessation
- 2011-07-07 US US13/178,428 patent/US9089510B2/en not_active Expired - Fee Related
- 2011-11-14 HK HK11112264.1A patent/HK1157795A1/xx not_active IP Right Cessation
-
2012
- 2012-02-14 US US13/396,543 patent/US9125847B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062765L (no) | Immunogene peptid-baerer konjugater og fremgangsmater for fremstilling av disse | |
WO2005058940A3 (en) | Immunogenic peptide carrier conjugates and methods of producing same | |
EP2925368B1 (en) | Methods for making conjugates from disulfide-containing proteins | |
Pechar et al. | Associative diblock copolymers of poly (ethylene glycol) and coiled‐coil peptides | |
Lagnoux et al. | Inhibition of mitosis by glycopeptide dendrimer conjugates of colchicine | |
BRPI0417341A (pt) | fator ix glicopeguilado | |
NO20080970L (no) | Glykopegylert faktor VII og faktor VIIA | |
NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
Nawroth et al. | Maleimide‐Functionalized Poly (2‐Oxazoline) s and Their Conjugation to Elastin‐Like Polypeptides | |
Tsukagoshi et al. | Basic Amino Acid Conjugates of 1, 2‐Diselenan‐4‐amine with Protein Disulfide Isomerase‐like Functions as a Manipulator of Protein Quality Control | |
Grandjean et al. | Synthesis of Clustered Glycoside–Antigen Conjugates by Two One‐Pot, Orthogonal, Chemoselective Ligation Reactions: Scope and Limitations | |
Kadereit et al. | Acid‐labile protecting groups for the synthesis of lipidated peptides | |
Kantchev et al. | Direct Fmoc/tert‐Bu solid phase synthesis of octamannosyl polylysine dendrimer–peptide conjugates | |
EP0468714A2 (en) | Peptide-polysaccharide-protein conjugate vaccines | |
Baigude et al. | Synthesis of structurally‐controlled AIDS vaccine model with glyco‐peptide dendrimer scaffolds | |
Uray et al. | The effect of glycosylation on the antibody recognition of a MUC2 mucin epitope | |
Euzen et al. | Synthesis of glycopeptide dendrimers, dimerization and affinity for Concanavalin A | |
Pillai et al. | A flexible method for preparation of peptide homo‐and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups | |
Bodero et al. | Synthesis and Biological Evaluation of an isoDGR‐Paclitaxel Conjugate Containing a Cell‐Penetrating Peptide to Promote Cellular Uptake | |
Cobo et al. | Probing Site‐Selective Conjugation Chemistries for the Construction of Homogeneous Synthetic Glycodendriproteins | |
TH115317B (th) | A(สูตร) อิมมูโนจีนิกเพปไทด์แคริเออร์คอนจูเกตและวิธีการผลิตสารเดียวกันนี้ | |
Vita et al. | Total synthesis of horse heart apocytochrome c by conformation‐assisted condensation of two chemically synthesized fragments | |
WO2004063214A3 (en) | Antibodies that specifically recognize sumo-conjugated proteins | |
TH115317A (th) | Ab อิมมูโนจีนิกเพปไทด์แคริเออร์คอนจูเกตและวิธีการผลิตสารเดียวกันนี้ | |
Vittur | Synthesis, Characterization, and Applications of a Melamine Based Dendrimer with Twelve Cysteine Groups on the Periphery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |